Antibacterial therapy with bacteriophage genotypically modified

Details Antibacterial therapy with bacteriophage genotypically modified Antibacterial therapy with bacteriophage genotypically modified

1995-06-05

1998-06-16

Marx, Irene

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Virus or bacteriophage

4352351, 435239, A61K 3576, C12N 702, C12N 708

Patent

active

057668922

ABSTRACT:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.

REFERENCES:
patent: 4332897 (1982-06-01), Nakano et al.
patent: 4375734 (1983-03-01), Kozloff et al.
patent: 4797363 (1989-01-01), Teodorescu et al.
patent: 4865979 (1989-09-01), Nakano et al.
patent: 5132221 (1992-07-01), Ward et al.
patent: 5344822 (1994-09-01), Levine et al.
Slopek, S. et al., Archivum Immunologiae et Therapiae Experimentalis, vol. 31, pp. 267-291, 1983.
Kaczkowski, H. et al., Wiad. Lek., vol. 43(3-4), pp. 136-141, 1990.
Bogovazova, et al., J. Micro., Epiderm, and Immune Biol., vol. 3, pp. 30-33 (1992).
Soothill, J. Med. Micro., vol. 37, pp. 258-261 (1992).
Mazacek, et a., Zentralbl. Bakteril., vol. 211, No. 3, pp. 385-394 (1969).
Kucharewicz-Krukowska, et al., Archivum Immunologiae et Therapiae Experimentalis, vol. 35, No. 5, pp. 553-568 (1987).
Cislo, et al., Archivum Immunologiae et Therapiae Experimentalis, vol. 35, No. 2, pp. 175-183 (1987).
Slopek, et al., Archivum Immunologiae et Therapiae Experimentalis, vol. 33, No. 2, pp. 219-240, 261-273 (1985).
Slopek, et al., Archivum Immunologiae et Therapiae Experimentalis, vol. 32, No. 2, pp. 317-335 (1984).
ATCC Catalogue of Bacteria and Phages, 18th ed., Rockville, MD, pp. 402-409 (1992).
Smith, et al., Jour. of Gen. Micro., vol. 133, pp. 1111-1126 (1987).
Smith, et al., Jour. of Gen. Micro., vol. 128, pp. 307-318 (1982).
Smith, et al., Jour. of Gen. Micro., vol. 129, pp. 2659-2675 (1983).
Soothill, et al., J. Med. Microbiol., vol. 37(4), pp. 258-261 (1992).
Roitt, Essential Immunology, Seventh Edition, pp. 110-113 Blackwell Scientific Publications.
Berchiere, Jr., et al., Res. Microbiol., "The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium", 1991, vol. 142, pp. 541-549.
Stent, G., Molecular Biology of Bacterial Viruses, W.H. Freeman & Co., (1963).
Bendinelli et al., Mycobacterium tuberculosis, pp. 311-313, Plenum Press.
Vymola et al., Staphylococcal Osteomyelitis, Annals New York Academy of Sciences.
Kress et al., "A Preliminary Report on the Use of Staphage Lysate for Treatment of Hidradenitis Suppurativa", pp. 393-395, May 1981 Little, Brown, and Co., Inc. Annals of Plastic Surgery vol. 6, #5.
Angel et al., Surgical Forum, "Beneficial Effects of Staphage Lysate in the Treatment of Chronic Recurrent Hidradenitis Suppurativa", pp. 111-112 vol. 38 (1987).
Salmon et al., The Journal of the Medical Society of New Jersey, "Staphage Lysate Therapy in Chronic Staphylococcal Infections", vol. 60, pp. 188-193 May, 1963.
Geier, M.R. et al. Nature, vol. 246, No. 5430, "Fate of Bacteriophage Lambda in Non-immune Germ-free Mice", pp. 221-222, Nov. 23, 1973.

Affiliated with

Also associated with

Rating

Antibacterial therapy with bacteriophage genotypically modified does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibacterial therapy with bacteriophage genotypically modified , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial therapy with bacteriophage genotypically modified will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1724401